Maa: Irlanti
Kieli: englanti
Lähde: HPRA (Health Products Regulatory Authority)
Febuxostat
Pinewood Laboratories Ltd
M04AA03
Febuxostat
80 milligram(s)
Film-coated tablet
Product subject to prescription which may be renewed (B)
febuxostat
Marketed
2018-11-30
1 PACKAGE LEAFLET: INFORMATION FOR THE USER FEBUXOSTAT PINEWOOD 80 MG FILM-COATED TABLETS FEBUXOSTAT PINEWOOD 120 MG FILM-COATED TABLETS febuxostat READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Febuxostat Pinewood is and what it is used for 2. What you need to know before you take Febuxostat Pinewood 3. How to take Febuxostat Pinewood 4. Possible side effects 5. How to store Febuxostat Pinewood 6. Contents of the pack and other information 1. WHAT FEBUXOSTAT PINEWOOD IS AND WHAT IT IS USED FOR Febuxostat Pinewood tablets contain the active substance febuxostat and are used to treat gout, which is associated with an excess of a chemical called uric acid (urate) in the body. In some people, the amount of uric acid builds up in the blood and may become too high to remain soluble. When this happens, urate crystals may form in and around the joints and kidneys. These crystals can cause sudden, severe pain, redness, warmth and swelling in a joint (known as a gout attack). Left untreated, larger deposits called tophi may form in and around joints. These tophi may cause joint and bone damage. Febuxostat Pinewood works by reducing uric acid levels. Keeping uric acid levels low by taking Febuxostat Pinewood once every day stops crystals building up, and over time it reduces symptoms. Keeping uric acid levels sufficiently low for a long enough period can also shrink tophi. Febuxostat Pinewood 120 mg tablets are also used to treat and prevent high blood levels of uric acid that may occur when you start to Lue koko asiakirja
Health Products Regulatory Authority 22 March 2023 CRN00CWWX Page 1 of 14 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Febuxostat Pinewood 80 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 80 mg of febuxostat (as magnesium salts). _Excipient(s) with known effect:_ Each tablet contains 76.50 mg lactose monohydrate. Each tablet contains 0.17 mmol (3.9 mg) sodium. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet (tablet) Pale yellow to yellow, film-coated, capsule shaped tablets, engraved with "80" on one side, 17.2 ± 0.2 mm in length, 6.2 ± 0.2 mm in width, 5.6 ± 0.2 mm in thickness. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis). Febuxostat Pinewood is indicated in adults. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The recommended oral dose of Febuxostat Pinewood is 80 mg once daily without regard to food. If serum uric acid is > 6 mg/dL (357 micromol/L) after 2-4 weeks, Febuxostat Pinewood 120 mg once daily may be considered. Febuxostat Pinewood works sufficiently quickly to allow retesting of the serum uric acid after 2 weeks. The therapeutic target is to decrease and maintain serum uric acid below 6 mg/dL (357 micromol/L). Gout flare prophylaxis of at least 6 months is recommended (see section 4.4). _ _ _Elderly_ No dose adjustment is required in the elderly (see section 5.2). _Renalimpairment_ The efficacy and safety have not been fully evaluated in patients with severe renal impairment (creatinine clearance < 30 mL/min, see section 5.2). No dose adjustment is necessary in patients with mild or moderate renal impairment. _ _ _Hepaticimpairment_ The efficacy and safety of febuxostat have not been studied in patients with severe hepatic impairment (Child-Pugh Class C). The recommended dose in patients with mild hepatic impairment Lue koko asiakirja